Finasteride-its impact on sexual function and prostate cancer
Finasteride, a specific and competitive inhibitor of 5a-reductase enzyme Type 2, inhibits the conversion of testosterone to dihydrotestosterone (DHT). In adults, DHT acts as primary androgen in prostate and hair follicles. The only FDA-approved dermatological indication of finasteride is androgeneti...
Main Authors: | Anitha B, Inamadar Arun, Ragunatha S |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2009-01-01
|
Series: | Journal of Cutaneous and Aesthetic Surgery |
Subjects: | |
Online Access: | http://www.jcasonline.com/article.asp?issn=0974-2077;year=2009;volume=2;issue=1;spage=12;epage=16;aulast=Anitha |
Similar Items
-
Prostate cancer and androgenic alopecia: The role of finasteride as a dual agent
by: Jabir Jassam
Published: (2021-01-01) -
THE RESULTS OF TREATMENT OF BENIGN PROSTATIC OBSTRUCTION WITH FINASTERIDE
by: Bojan Tršinar
Published: (2001-12-01) -
Finasteride and sexual side effects
by: Venkataram Mysore
Published: (2012-01-01) -
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
by: Yu Seob Shin, et al.
Published: (2019-05-01) -
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer
by: Jeri Kim, et al.
Published: (2016-05-01)